We are not turning bearish on biotech at this point. But we do think it’s a good time to be patient and to consider some portfolio protection. Read More
Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine. He has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.
Analyst Articles
We are not turning bearish on biotech at this point. But we do think it’s a good time to be patient and to consider some portfolio protection. Read More
Masimo Corporation (MASI) looks ready to move decidedly higher as it approaches its earnings release on August 5 at 4 P.M. Like our other biotech portfolio picks, this is a well run company with cash on its balance sheet and a growth agenda. In fact, Masimo has a nice stash… Read More
Masimo Corporation (MASI) looks ready to move decidedly higher as it approaches its earnings release on August 5 at 4 P.M. Like our other biotech portfolio picks, this is a well run company with cash on its balance sheet and a growth agenda. In fact, Masimo has a nice stash… Read More
- July 21, 2015
-
Download Issue
For those who have not been keeping score, the Nasdaq Biotech Index (NBI) is up over 33% in 2015 as of July 17 while S & P 500 is just over 3% for the year. Read More
For those who have not been keeping score, the Nasdaq Biotech Index (NBI) is up over 33% in 2015 as of July 17 while S & P 500 is just over 3% for the year. Read More
In this issue:In Depth: New EBIS Buy: Meridian Biosciences (VIVO)Portfolio Update: News on Repligen, Medivation, News Update: Are Migraines the Next Biotech Frontier?This week we are featuring two Big Picture charts as an interesting relationship is developing between the biotech sector and the bond market. The Nasdaq Biotech Index (NBI) delivered… Read More
In this issue:In Depth: New EBIS Buy: Meridian Biosciences (VIVO)Portfolio Update: News on Repligen, Medivation, News Update: Are Migraines the Next Biotech Frontier?This week we are featuring two Big Picture charts as an interesting relationship is developing between the biotech sector and the bond market. The Nasdaq Biotech Index (NBI) delivered… Read More
- June 15, 2015
-
Download Issue
Today, we reveal our method for selecting portfolio recommendations using a system based on fundamental analysis of emerging biotech companies. Read More
- May 18, 2015
-
Download Issue
Resources are tightening up and that means that any new drugs that come to the market and deliver tangible financial results have to live up to a higher standard than before. Read More